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Background: Ischemia-reperfusion injury (IRI) has been considered an inevitable event
in organ transplantation since the first successful kidney transplant was performed
in 1954. To avoid IRI, we have established a novel procedure called ischemia-free
organ transplantation. Here, we describe the first case of ischemia-free kidney
transplantation (IFKT).
Materials and Methods: The kidney graft was donated by a 19-year-old brain-dead
donor. The recipient was a 47-year-old man with end-stage diabetic nephropathy. The
graft was procured, preserved, and implanted without cessation of blood supply using
normothermic machine perfusion.
Results: The graft appearance, perfusion flow, and urine production suggested that
the kidney was functioning well-during the whole procedure. The creatinine dropped
rapidly to normal range within 3 days post-transplantation. The levels of serum renal
injury markers were low post-transplantation. No rejection or vascular or infectious
complications occurred. The patient had an uneventful recovery.
Conclusion: This paper marks the first case of IFKT in humans. This innovation may
offer a unique solution to optimizing transplant outcomes in kidney transplantation.
Keywords: kidney transplantation, ischemia-reperfusion injury, normothermic machine perfusion, ischemia-free
kidney transplantation, ischemia-free organ transplantation
INTRODUCTION
Since the first successful case of kidney transplantation was performed in 1954 (1), all transplant
procedures have caused cessation of blood supply to donor organs during procurement,
preservation, and implantation. The subsequent restoration of blood supply after ischemia
exacerbates the initial cellular damage; this is known as ischemia-reperfusion injury (IRI) (2). Not
only can IRI lead to primary non-function (PNF) or delayed graft function (DGF) in the early stage,
but it can also cause chronic fibrosis and allograft rejection in the long run (3).
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For decades, great efforts have been made to treat IRI (4).
However, limited success has been achieved because none of
the research methods is able to prevent the donor organs from
experiencing initial ischemic injury. It has been shown that
hypothermic machine perfusion (HMP) is superior to static
cold storage (SCS) in preserving donor kidneys (5). Recently,
the Leicester group has translated the use of normothermic
machine perfusion (NMP) from animal studies to clinical use and
performed the first kidney transplantation in a male patient after
60min of ex vivoNMP in 2011 (6). Since then, the same group has
used NMP for assessment and resuscitation of marginal donor
kidneys (7, 8). However, since they used NMP following many
hours of SCS, ischemic injury of grafts and subsequent IRI was
still inevitable.
We have established a novel procedure called ischemia-free
liver transplantation (IFLT) during which the donor livers can
be procured, preserved, and implanted without cessation of
oxygenated blood supply to the grafts (9). During IFLT, IRI can
be largely avoided. In this study, we report the first case of
ischemia-free kidney transplantation (IFKT).
CASE PRESENTATION
The kidney donor was a 19-year-old male patient who died
of a craniocerebral trauma. The terminal serum creatinine was
54 µmol/L. The donor and recipient were co-located in the
First Affiliated Hospital of Sun Yat-sen University. The left
kidney was procured after ligating the left renal artery and vein
FIGURE 1 | (A) Ischemia-free kidney transplant procedure. The diagram shows procurement, preservation, and implantation of the donor kidney without cessation of
blood supply using normothermic machine perfusion. (B) Normothermic machine perfusion device, Liver Assist (Organ Assist, Groningen, the Netherlands). (C) Donor
kidney circuit on the organ reservoir of the NMP device.
and immediately cold flushed through the left kidney artery.
This graft was preserved in ice-cold University of Wisconsin
solution. The right kidney was subjected to IFKT. The study
protocol was approved by the Ethical Committee of our hospital.
Written informed consent for the publication of the case report
was obtained from the patient undergoing this ischemia-free
kidney transplantation.
IFKT PROCEDURE
Figure 1A shows the technical details of the procedure. Firstly,
the abdominal aorta (AA) and right renal artery, inferior vena
cava (IVC), and right renal vein were well-dissected. The ureter
was cut off, and a tube was placed in the ureter for urine
drainage. A 34Fr caval cannula was placed in the infrarenal
IVC for blood outflow to the organ reservoir of the Liver Assist
device (Organ Assist, Groningen, the Netherlands, Figure 1B).
A straight 20Fr cannula was inserted into the infrarenal AA of
the donor. Subsequently, the arterial cannula was connected to
the artery perfusion line of Liver Assist, and the suprarenal AA
was blocked. The venous drainage of suprarenal IVC was also
blocked. After the circuit of in vivo NMP was established, the
right kidney was harvested and moved to the organ reservoir for
ex vivo NMP (Figure 1C). Simultaneously, the donor liver was
procured after cold flush via a cannula in the superior mesenteric
vein. We sutured part of the suprarenal IVC with 6-0 Prolene
and reduced its diameter to 1.5 cm on the organ reservoir of
NMP ex vivo.
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TABLE 1 | Components of the perfusate solution.
Components
Crossed-matched leucocyte-depleted washed red cells 1,000 mL
Sodium, potassium, magnesium, calcium, and glucose injection 600 mL
Succinylated gelatinor 400 mL
5% sodium bicarbonate 50 mL
Heparin 25,000 units
Metronidazole 0.5 g
Miropeen for injection 1 g
10% calcium gluconate 8 mL
Compound amino acid injection 40 mL
Dexamethason 15 mg
Insulin 100 units
20% mannitol 20 mL
The kidney graft underwent continuous NMP for 110min.
The perfusate components are shown in Table 1. The perfusate
was warmed up to 37◦C, and the oxygenator was supplied with
air. The viability of the graft was assessed based on the appearance
of graft and perfusion flow, as well as urine production. No
creatinine was added to the perfusate for the graft function
test. The perfusion pressure (52–70 mmHg) and flow (130–184
mL/min) were stable during the whole procedure (Figure 2A).
The creatinine and urea levels in the perfusate were stable and
low (Figure 2B). The kidney graft continued to produce urine
during the whole procedure (Figure 2C). The pH values and
specific gravity of the urine produced before procurement were
comparable to those produced during NMP and after reperfusion
(Figure 2D).
The donor kidney was then moved from the reservoir and
placed in the right iliac fossa of the recipient so that an in
vivo NMP circuit was re-established. The donor suprarenal AA
and suprarenal IVC were anastomosed to the recipient right
external iliac artery and vein in an end-to-side fashion using 6-
0 Prolene. During the vascular anastomoses, caution was taken
to prevent twisted perfusion lines. After that, the clamp on
the donor suprarenal AA was released so that recipient blood
supply for the donor kidney was established. In the meantime,
NMP was stopped. Around 50mL perfusate was flushed out
of the kidney, followed by release of the clamp on the donor
suprarenal IVC. The cannulas in the IVC and AA were removed,
and the infrarenal IVC and AA were sutured closed. Finally,
after withdrawal of the draining tube, the donor ureter was
anastomosed to the bladder of the recipient. The recipient
operation time was 135 min.
OUTCOMES
The recipient was a 47-year-old man with diabetic nephropathy
who had been on hemodialysis for more than 2 years. The
recipient had immediate graft function, and the serum creatinine
levels fell from 1100µmol/L pre-transplantation to 95µmol/L on
post-operative day (POD) 3 (Figure 3A). The mean urine output
over the first 5 days post-transplantation was 4,987 mL/day
compared with a pre-transplant daily output of <100 mL.
The post-transplant estimated glomerular filtration rate
(eGFR) increased from 3.99 mL/min/1.73m2 pre-transplantation
to 103.28 mL/min/1.73m2 on POD 7 (Figure 3B). The post-
transplant level of cystatin C (Cys C) was quite low (1.76 mg/L
on POD 1 and 1.26 mg/L on POD 7) (Figure 3C). The levels
of other serum kidney injury biomarkers (10–13), including
neutrophil gelatinase-associated lipocalin (NGAL), liver fatty
acid-binding protein (L-FABP), kidney injury molecule-1 (KIM-
1), and glutathione s-transferase alpha 1 (GSTA1), all sharply
decreased after IFKT (Figures 3D–G). No acute rejection, renal
artery or renal vein thrombosis, or infectious complications
occurred. The patient was discharged with a serum creatinine of
80 µmol/L on POD 15.
DISCUSSION
Kidney transplantation is inevitably associated with IRI, which
can cause acute cellular injury and renal dysfunction (14–18).
Several methods to ameliorate IRI have been proposed, including
ischemic pre-conditioning, pharmacological interventions,
protective gases, and gene and stem cell therapies (4). However,
few of these methods have been translated into clinical practice.
In contrast to the intention to “treat” IRI in earlier studies
(4), our group focused on “preventing” IRI. We have shown
that the concept of ischemia-free organ transplantation (IFOT)
is feasible, safe, and effective in liver transplantation (9).
Histological analysis, inflammatory cytokine production, and
pathway analysis suggested that IRI is largely avoidable.
In this case report, we showed for the first time that
IFOT can be expanded to kidney transplantation. The kidney
was continuously functioning, with urine production during
procurement, preservation, and implantation during IFKT. The
serum creatinine dropped rapidly to normal range within 3
days, and eGFR increased rapidly post-transplantation. A recent
study indicated that CysC can maintain its predictive power for
adverse outcomes in patients with no meaningful GFR (19). The
serum CysC level and the other renal injury markers were quite
low post-transplantation. Since the kidney experienced ongoing
NMP, for the safety of the recipient, no biopsy was obtained
to confirm the absence of IRI. The recipient had an uneventful
recovery without infectious or surgical complications.
Successful IFKT is established based on efficient NMP. To our
knowledge, all studies concerning kidney NMP in humans are
from the Leicester group (6, 7, 20, 21). They have reported that
NMP can resuscitate human kidneys deemed untransplantable
and can help assess kidney quality (20, 21). Moreover, the use of
NMP is associated with significant decrease in DGF (6). However,
the 1-h NMP is preceded by a period of cold storage after
procurement and followed by a cold flush before implantation.
Therefore, ischemic injury and subsequent graft IRI are still
unavoidable. In contrast, IFKTmaintains continuous oxygenated
blood supply to the kidney, and thus IRI is probably avoided, and
this may further reduce the DGF rate and improve long-term
outcome after kidney transplantation, although the donor and
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FIGURE 2 | Normothermic machine perfusion and allograft viability. (A) Arterial flow rates and pressure. (B) Creatinine (Crea) and urea concentration in the perfusate.
(C) Volume of urine production during machine perfusion. (D) pH values and specific gravity levels of the urine produced before procurement, during machine
perfusion, and post-reperfusion.
FIGURE 3 | Post-transplant renal function and serum biomarker levels of kidney injury of the recipient. The renal function tests including (A) creatinine (Crea) and (B)
estimated glomerular filtration rate (eGFR). The serum biomarker levels of kidney injury including (C) cystatin C, (D) neutrophil gelatinase-associated lipocalin (NGAL),
(E) liver fatty acid-binding protein (L-FABP), (F) kidney injury molecule-1 (KIM-1), and (G) glutathione s-transferase alpha 1 (GSTA1).
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recipient need to be at the same hospital because of the limited
NMP time. This method may be more useful in expanded criteria
donor (ECD) kidneys, since ECD kidneys are more susceptible
to IRI. It would be highly interesting to compare the transplant
outcomes of IFKT, kidney transplantation using NMP as a
preservationmethod, and conventional kidney transplantation in
the future.
Undoubtedly, there are several limitations to this study.
Firstly, the donor and recipient are usually not co-located.
Therefore, a portable kidney NMP device is required for this
procedure. However, to our knowledge, this kind of device is not
commercially available. Secondly, it is difficult to conduct IFKT
of both donor kidneys for two recipients. In addition, although
serum kidney injury marker levels have been tested to assess
IRI severity, a biopsy of the graft should be done to confirm
the absence of IRI. Finally, the kidney in this case was from a
young standard brain-death donor. No significant difference in
transplant outcomes and renal graft function was documented
between the two recipients of the left and right renal grafts. The
potential benefits should be tested in a prospective, randomized
controlled study in a predefined subgroup of ECD kidneys.
In summary, we report here that IFKT is technically feasible.
This innovation might be able to optimize transplant outcomes
and maximize graft utilization.
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